Effects of Hormone Replacement Therapy on the Serotonergic System and Mood in Postmenopausal Women

Study Overview
=================
Brief Summary
-----------------
Menopausal and postmenopausal women compose almost 20% of the Austrian population. Two thirds of all austrian women suffering from depression or anxiety disorders are over 45 years old. The serotonergic system, partially regulated by the steroid hormones estrogen and progesterone, plays a major role in the pathogenesis and treatment of these illnesses. To examine the effect of the hormone replacement therapy on the serotonergic system, twenty-four postmenopausal women will be measured using positron emission tomography (PET). The volunteers will participate in two PET scans. The first PET scan will be performed right before the hormone treatment starts, the second PET scan about 8 weeks after daily treatment with (1) a combination of estrogen and progesterone or (2) estrogen and placebo. This imaging study hypothesizes that the expression of the main inhibiting serotonergic receptor (the serotonin-1A receptor) will be altered by the hormone therapy. The results of the study might lead to new strategies in the treatment of psychiatric illnesses during and after the menopausal transition.

Official Title
-----------------
The Influence of Hormone Replacement Therapy on the Cerebral Serotonin-1A Receptor Distribution and Mood in Postmenopausal Women

Conditions
-----------------
Hormone Replacement

Intervention / Treatment
-----------------
* Drug: estradiol valerate
* Drug: micronized progesterone
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Postmenopausal females (over 14 months of amenorrhoea) Age 50 - 65 years Signed informed consent form Consent not to participate in PET or SPECT studies with an added equivalence dose of over 15 mSv within 10 years following the final assessment of the participant in this study Exclusion criteria Steroid hormone treatment within 6 months prior to the inclusion Current substance abuse History of any malign illness Any implant or stainless steel graft Concomitant neurological illness Concomitant psychiatric disorder except anxiety disorders or depression Treatment with a psychotropic agent targeting serotonin-1A and serotonin-2A receptors or the serotonin transporter such as buspirone, pindolol or SSRIs Clinically relevant abnormalities in the general physical examination and the routine laboratory screening Concomitant major illness, especially: liver disease, disorders of the endocrine system, osteoporosis (when treated with vitamine D), any clinically relevant vascular or heart diseases One of the following gynaecological diseases: ovariectomy, hysterectomy, endometriosis, cervical smear test: PAP > II Failures to comply with the study protocol or to follow the instructions of the investigating team Investigations using PET or SPECT within 10 years prior to the inclusion

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: estradiol valerate<br>* Progynova® 21; 2mg/d<br>Drug: micronized progesterone<br>* Utrogestan®; 200mg/d<br>|
| Experimental: 2<br> | Drug: estradiol valerate<br>* Progynova® 21; 2mg/d<br>|
| Placebo Comparator: 3<br>Placebo | Drug: placebo<br>* maltodextrin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serotonin-1A receptor binding potential |  | 24 months |